Nephros (FRA:NPJP) Cash And Cash Equivalents : €3.78 Mil (As of Mar. 2025)

View and export this data going back to 2023. Start your Free Trial

What is Nephros Cash And Cash Equivalents?

Nephros's quarterly cash and cash equivalents increased from Sep. 2024 (€2.21 Mil) to Dec. 2024 (€3.59 Mil) and increased from Dec. 2024 (€3.59 Mil) to Mar. 2025 (€3.78 Mil).

Nephros's annual cash and cash equivalents increased from Dec. 2022 (€3.43 Mil) to Dec. 2023 (€3.95 Mil) but then declined from Dec. 2023 (€3.95 Mil) to Dec. 2024 (€3.59 Mil).

Nephros Cash And Cash Equivalents Historical Data

The historical data trend for Nephros's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nephros Cash And Cash Equivalents Chart

Nephros Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash And Cash Equivalents

Get a 7-Day Free Trial

6.78

6.17

3.43

3.95

3.59

Nephros Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Cash And Cash Equivalents	Get a 7-Day Free Trial															3.34	2.86	2.21	3.59	3.78

Nephros Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Nephros (FRA:NPJP) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Nephros Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Nephros's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Nephros Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nephros Inc (FRA:NPJP) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

NEPH:USA

Address

380 Lackawanna Place, South Orange, NJ, USA, 07079

Website

https://www.nephros.com

Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.

Nephros Headlines

No Headlines